Product Focus — Pertussis Toxin (PTX), a Key Tool for Molecular Interaction Research
Pertussis Toxin (PTX) is a major virulence factor produced by Bordetella pertussis, the causative agent of whooping cough. It possesses diverse biological activities, which are responsible for numerous clinical symptoms of whooping cough, and it also serves as a primary immunogen. PTX binds to most mammalian cultured cells and specifically targets G proteins, thereby inhibiting G proteins and their physiological functions in signal transduction pathways. Precisely, its ability to inhibit signal pathways through Gi family protein-coupled receptors makes PTX an indispensable tool in cell biology research.
Groups: QRFPR-WT, QRFPR-N5Q, QRFPR-N19Q, QRFPR-N106Q; Treatments: Hanks-PTX, DMSO-FR900359, DMSO, Hanks; Detection Indicators: Ca²+ Influx (Fluorescence Intensity); X-axis: Time (s); Y-axis: Fluorescence Intensity)
Meanwhile, PTX is a core component of all currently available whooping cough vaccines, and the presence of antibodies against this toxin is associated with protecting children from whooping cough. Therefore, PTX will likely continue to be a crucial component of whooping cough vaccines. However, as an exotoxin, genetic modification of its structural genes for detoxification may prompt vaccine manufacturers to shift from chemically detoxified acellular pertussis vaccines (APV) to genetically detoxified APV. Genetically detoxified PTX exhibits superior safety and immunogenicity compared to chemically detoxified PTX. Nevertheless, even with the transition to genetically detoxified PTX, APV may still fail to prevent B. pertussis infection. To achieve this goal, further research on the pathogenic mechanism, immunological changes, and antigenic components of whooping cough is essential, thereby facilitating the development of a novel whooping cough vaccine with long-term immunity and the ability to prevent B. pertussis infection [2].
|
1. Catalyzes the transfer of the ADP-ribose moiety of NAD to the α-subunit of heterotrimeric Gi/o proteins, resulting in uncoupling of receptors from Gi/o proteins [3,4]. 2. Animal model for Multiple Sclerosis (MS): Co-injection with specific antigens to establish the Experimental Autoimmune Encephalomyelitis (EAE) model [5,6]. 3. Development of acellular pertussis vaccines with higher safety and protective efficacy. |
|
Product Code |
Product Name |
Specification |
|
abs42024900 |
Pertussis Toxin |
50μg |
All products of ANT BIO PTE. LTD. are for scientific research use only. They shall not be used for medicinal, household, or other purposes.
[1] Wang WW, Tian YN, Shi XL, et al. N-glycosylation of the human neuropeptide QRFP receptor (QRFPR) is essential for ligand binding and receptor activation[J]. Journal of Neurochemistry. 2021,158:138-152.
[2] Li X, Zhang X C, Xie G L. Research Progress of Pertussis Toxin[J]. Chinese Journal of Biologicals. 2018.
[3] Kaslow HR. Pertussis toxin and target eukaryotic cells: binding, entry, and activation[J]. Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology, 1992, 6(9):2684-2690.
[4] Ui M. Islet-activating protein, pertussis toxin: a probe for functions of the inhibitory guanine nucleotide regulatory component of adenylate cyclase[J]. Trends in Pharmacological Sciences, 1984, 5(7):277-279.
[5] Hofstetter HH, Shive CL, Forsthuber TG. Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells[J]. Journal of Immunology, 2002, 169(1):117-125.
[6] Ronchi F, Basso C, Preite S, et al. Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1β production by myeloid cells[J]. Nature Communications. 2016.
ANT BIO PTE. LTD. is dedicated to advancing life science research by providing high-quality, reliable reagents and comprehensive solutions. We recognize the critical challenges in molecular interaction research and the urgent need for standardized, specialized experimental tools. Through our specialized sub-brands (Absin, Starter, UA), we have developed a targeted product portfolio for molecular interaction and immunology research, covering core tools such as Pertussis Toxin and related supporting reagents.
Our team adheres to stringent quality control standards throughout the product development and production process, ensuring the high purity, stability, and biological activity of each product. We are committed to providing professional technical support and customer-centric services, helping researchers overcome experimental challenges such as specific targeting of G protein signaling pathways and establishment of autoimmune disease models, and accelerating the pace of scientific research breakthroughs in molecular interaction, immunology, and vaccine development-related fields. ANT BIO PTE. LTD. strives to be a trusted partner for scientists worldwide, contributing to the advancement of molecular biology research technology and the development of innovative disease prevention and treatment strategies.
This article is AI-compiled and interpreted based on the original work related to Pertussis Toxin research. All intellectual property (e.g., experimental protocols, data, images) of the original publication shall belong to the relevant research team. For any infringement, please contact us promptly and we will take immediate action.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of molecular interaction and immunology research needs, from core tools like Pertussis Toxin to related supporting products. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in overcoming molecular interaction research challenges and driving progress in immunology and vaccine development. Explore our product portfolio today and elevate your research to new heights.
